Cytokinetics' MYQORZO Launched in Germany for Obstructive HCM
Cytokinetics has initiated the commercial launch of MYQORZO (aficamten) in Germany, targeting symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows European Commission approval in February and previous regulatory clearances in the United States and China. MYQORZO, a cardiac myosin inhibitor, demonstrated significant improvements in patient outcomes during its Phase 3 clinical trials, marking a crucial step in the company's European expansion strategy.

